Optimal Dosages of Fluoxetine in the Treatment of Hypoxic Brain Injury Induced by 3-Nitropropionic Acid: Implications for the Adjunctive Treatment of Patients after Acute Ischemic Stroke

CNS Neuroscience and Therapeutics

Volumn 18, Issue 7, 2012, Pages 530-535

  Zhu, Bing Gen ^a   Sun, Yan ^a   Sun, Zhi Qi ^a   Yang, Guang ^a   Zhou, Cheng Hao ^a   Zhu, Rong Shen ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

3 nitropropionic acid; Acute ischemic stroke; Fluoxetine; Hypoxic brain injury

Indexed keywords

3 NITROPROPIONIC ACID; 8 HYDROXYDEOXYGUANOSINE; FLUOXETINE; MALONALDEHYDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN HOMOGENATE; BRAIN HYPOXIA; BRAIN INJURY; BRAIN ISCHEMIA; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; DNA DAMAGE; DOSE RESPONSE; DRUG MEGADOSE; LIPID PEROXIDATION; MALE; MOTOR DYSFUNCTION; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; ROTAROD TEST;

ANIMALS; BRAIN ISCHEMIA; FLUOXETINE; HYPOXIA, BRAIN; MALE; MICE; NITRO COMPOUNDS; PROPIONATES; RANDOM ALLOCATION; STROKE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84863504689     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2012.00315.x     Document Type: Article

References (48)

1. Lauterbach EC, Victoroff J, Coburn KL, Shillcutt SD, Doonan SM, Mendez MF. Psychopharmacological neuroprotection in neurodegenerative disease: Assessing the preclinical data. J Neuropsychiatry Clin Neurosci 2010;22:8-18.
2. Duman RS. Neuronal damage and protection in the pathophysiology and treatment of psychiatric illness: Depression. Dialogues Clin Neurosci 2009;11:239-255.
3. Mckernan DP, Dinan TG, Cryan JF. "Killing the blues": A role for cellular suicide (apoptosis) in depression and the antidepressant response? Prog Neurobiol 2009;88:246-263.
4. Mostert JP, Koch MW, Heerings M, Heersema DJ, De Keyser J. Therapeutic potential of Fluoxetine in neurological disorders. CNS Neurosci Therapeutics 2008;14:153-164.
5. Egeland M, Warner-Schmidt J, Greengard P, Svenniningsson P. Neurogenic effects of fluoxetine are attenuated in p11 (S100A10) knockout mice. Biol Psychiatry 2010;67:1048-1056.
6. Koch JM, Kell S, Aldenhoff JB. Differntial effects of fluoxetine and imipramine on the phosphorylation of the transcription factor CREB and cell-viability. J Psychiat Res 2003;37:53-59.
7. Ohira K, Miyakawa T. Chronic treatment with fluoxetine for more than 6 weeks decreases neurogenesis in the subventricular zone of adult mice. Mol Brain 2011;4:10-22.
8. Sairanen M, Lucas G, Ernfors P, Castren M, Castren E. Brain-derived neurotrophic factor and antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation, and survival in the adult dentate gyrus. J Neurosci 2005;25:1089-1094.
9. Chang YC, Tzeng SF, Yu L, et al. Early-life flouxetine exposure reduced functional deficits after hypoxic-ischemia brain injury in rat pups. Neurobio Disease 2006;24:101-113.
10. Berends HI, Nijlant JMM, Movig KLL, van Putten MJAM, Jannink MJA, Ijzerman MJ. The clinical use of drugs influencing neurotransmitters in the brain to promote motor recovery after stroke: A Cochrane systematic review. Eur J Phys Rehabil Med 2009a;45:621-630.
11. Choi-kwon S, Han SW, Kwom SU, Kang DW, Choi JM, Kim JS. Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness (a double-blind, placebo-controlled study). Stoke 2006;37:156-161.
12. Narushima K, Paradiso S, Moser DJ, Jorge R, Robinson RG. Effects of antidepressant therapy on executive function after stroke. Br J Psychiatry 2007;190:260-265.
13. Yi ZM, Liu F, Zhai SD. Fluoxetine for the prophylaxis of poststroke depression in patients with stroke: A meta-analysis. Int J Clin Pract 2010;64:1310-1317.
14. Chollet F, Tardy J, Albucher JF, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): A randomized placebo-controlled trial. Lancet Neurol 2011;10:123-130.
15. Robinson RG, Adams HP. Selective serotonin-reuptake inhibitors and recovery after stroke. Lancet Neurol 2011;10:110-111.
16. Gram LF. Floxetine. N Engl J Med 1994;331:1354-1361.
17. Etain B, Bonnet-Perrin E. Value of fluoxetine in obsessive-compulsive disorder in the adult: Review of the literature. Encephale 2001;27:280-289.
18. Farnam A, Goreishizadeh MA, Farhang S. Effectiveness of fluoxetine on various subtypes of obsessive-compulsive disorder. Arch Iran Med 2008;11:522-525.
19. Cavaljuga S, Licanin I, Kapic E, Potkonjak D. Clomipramine and fluoxetine effects in the treatment of panic disorder. Bosn. J Basic Med Sci 2003;3:27-31.
20. Bacaltchuk J, Hay P. Antidepressants versus placebo for people with bulimia nervosa. Cochrane Database Syst Rev CD003391, 2003.
21. Leombruni P, Piero A, Lavagnino L, Brustolin A, Campisi S, Fassino S. A randomized, double-blind trial comparing sertraline and fluoxetine 6-month treatment in obese patients with Binge Eating Disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1599-1605.
22. Mostert JP, Sijens PE, Oudkerk M, De Keyser J. Fluoxetine increases cerebral white matter NAA/Cr ratio in patients with multiple sclerosis. Neurosci Lett 2006;402:22-24.
23. Sijens PE, Mostert JP, Irwan R, Potze JH, Oudkerk M, De Keyser J. Impact of fluoxetine on the human brain in multiple sclerosis as quantified by proton magnetic resonance spectroscopy and diffusion tensor imaging. Psychiatry Res 2008;164:274-282.
24. Munch C, Zhu B, Leven A, et al. Differential regulation of 5' splice variants of the glutamate transporter EAAT2 in an in vivo model of chemical hypoxia induced by 3-nitropropionic acid. J Neurosci Res 2003;71:819-825.
25. Fernagut PO, Diguet E, Stefanova N, et al. Subacute systemic 3-nitropropionic acid intoxication induces a distinct motor disorder in adult C57Bl/6 mice: Behavioural and histopathological characterization. Neuroscience 2002;114:1005-1017.
26. Li XM, Zhu BG, Ma S, et al. Depressive-like behavior in mice recently recovered from motor disorders after 3-nitropropionic acid intoxication. Neurosci Bull 2008;24:225-230.
27. Kumar P, Kalonia H, Kumar A. Novel protective mechanisms of antidepressants against 3-nitropropionic acid induced Huntington's-like symptoms: A comparative study. J Psychopharmacol 2011;25:1399-1411.
28. Kumar P, Kalonia H, Kumar A. Nitric oxide mechanism in the protective effect of antidepressants against 3-nitropropionic acid-induced cognitive deficit, glutathione and mitochondrial alterations in animal model of Huntington's disease. Behav Pharmacol 2010;21:217-230.
29. Kumar P, Kumar A. Possible role of sertraline against 3-nitropropionic acid induced behavioral, oxidative stress and mitochondrial dysfunctions in rat brain. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:100-108.
30. Austin EW, Parrish JM, Kinder DH, Bull RB. Lipid peroxidation and formation of 8-hydroxydeoxyguanosine from acute doses of halogenated acetic acids. Fund Appl Toxicol 1996;31:77-82.
31. Kouda K, Nakamura H, Fan W, Horiuchi K, Takeuchi H. The relationship of oxidative DNA damage marker 8-hydroxydeoxyguanosine and glycoxidative damage marker pentosidine. Clin Biochem 2001;34:247-250.
32. Olsen BJ, Markwell J. Assays for the determination of protein concentration. Curr Protoc Protein Sci 2007;48(suppl):3.4.14-3.4.17.
33. Balu DT. Enhanced sensitivity of the MRL/MpJ mouse to the neuroplastic and behavioral effects of acute and chronic antidepressant treatments. Exp Clin Psychopharmacol 2010;18:71-77.
34. Balu DT, Hodes G, Anderson BT, Lucki I. Enhanced sensitivity of the MRL/MpJ mouse to the neuroplastic and behavioral effects of chronic antidepressant treatments. Neuropsychopharmacology 2009;34:1764-1773.
35. David DJ, Samuels BA, Rainer Q, et al. Neurogenesis-dependent and -independent effects of fluxetine in an animal model of anxiety/depression. Neuron 2009;62:479-493.
36. Dulawa SC, Holick KA, Gundersen B, Hen R. Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology 2004;29:1321-1330.
37. Li WL, Cai HH, Wang B, et al. Chronic fluoxetine treatment improves ischemia-induced spatial cognitive deficits through increasing hippocampal neurogenesis after stroke. J Neurosci Res 2009;87:112-122.
38. Traugott U, Trego V. Fluoxetine greatly inhibits disease progression in chronic experimental allergic encephalomyelitis (EAE) in SJL/J mice. Neurology 1997;48:A422-A422.
39. , s disease. J Neurochem 2005;95:1521-540.
40. Muck-Seler D, Jevric-Causevic A, Diksic M. Influence of fluoxetine on regional serotonin synthesis in the rat brain. J Neurochem 1996;67:2434-2442.
41. Perry K, Fuller R. Effect of fluoxetine on serotonin and dopamine concentration in microdialysis fluid from rat striatum. Life Sci 1992;50:1683-1690.
42. Berends HI, Nijlant JMM, van Putten MJAM, Movig KLL, Ijzerman MJ. Single dose of fluoxetine increases muscle activation in chronic stroke patients. Clin Neuropharm 2009b;32:1-5.
43. Jacobs BL, Fornal CA. Serotonin and motor activity. Curr Opin Nuerobiol 1997;7:820-825.
44. Curti C, Mingatto FE, Polizello AC, Galastri LO, Uyemura SA, Santos AC. Fluoxetine interacts with the lipid bilayer of the inner membrane in isolated rat brain mitochondria, inhibiting electron transport and F1F0-ATPase activity. Mol Cell Biochem 1999;199:103-109.
45. Souza ME, Polizello AC, Uyemura SA, Castro-Silva O, Curti C. Effect of fluoxetine on rat liver mitochondria. Biochem Pharmacol 1994;48:535-541.
46. Abdel-Razaq W, Kendal DA, Bates TE. The effects of antidepressants on mitochondrial function in a model cell system and isolated mitochondria. Neurochem Res 2011;36:327-338.
47. De Luca G, Russo MT, Degan P, et al. A role for oxidized DNA precursors in Huntington's disease-like striatal neurodegeneration. Plos Genet 2008;4:e1000266.
48. Liu S, Levine SR. The continued promise of neuroprotection for acute stroke treatment. J Exp Stroke Transl Med 2008;1:1-8.